← British American Tobacco overview

British American Tobacco vs Turning Point Brands: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

British American Tobacco PLC (BATS.LSE)

Q3 2026
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

August 2026
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

Latest
▲2▼1

BAT's smoke-free push gets regulatory tailwind but revenue growth stays soft

  • US opens fast lane for vapes and pouches The Trump administration plans to speed up FDA approval of flavored vapes and nicotine pouches, cutting years of backlog. For BAT, faster clearances mean its Vuse and Velo products can reach US shelves sooner, lifting future sales and profit. Public health and youth-vaping objections could still slow or water down the rules.

    This is the biggest new regulatory force that can lift BAT's smoke-free sales in its largest market.

  • Modern Oral sales surge, buyback and higher EPS guidance BAT raised its full-year earnings guidance and announced a £1.3 billion share buyback after new-category revenue jumped 18%, led by a 66% rise in Modern Oral. Buybacks shrink the number of shares, which lifts earnings per share. Heated tobacco revenue fell nearly 12%, a weak spot.

    It shows the core profit engine and cash returns that directly support the share price.

  • Full-year revenue growth guided to low end BAT reaffirmed 2026 revenue growth at the low end of its 3% to 5% range, signalling softer top-line momentum. The stock is down 13.78% over 90 days. Long-term returns remain strong, and the shares trade below the company's estimated fair value, so the setback is about pace, not survival.

    It is the main new negative that explains why the shares have been weak despite good profit news.

  • Rival ZYN gets first-mover US advantage Philip Morris won the first FDA modified-risk status for a nicotine pouch and is doubling ZYN investment with a $1.2 billion Colorado plant. That gives a rival a head start in the fast-growing US pouch market. BAT's own Modern Oral revenue still rose 65.9%, and it plans a national Velo Max rollout, so it is not standing still.

    It is the key competitive counterweight to BAT's otherwise strong smoke-free growth story.

Q2 2026
▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

June 2026
▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

  • New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.

    Directly explains a positive price move and shows management's confidence.

  • 9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.

    This is the main new event and explains both the cost-saving upside and the demand-driven downside.

  • Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.

    Highlights the underlying demand problem that forces the restructuring and affects future revenue.

Turning Point Brands Inc (TPB)